SCHEMBL24317388

SCHEMBL24317388

CCOC(=O)c1ccc(Cc2ccc3c4c(cccc24)NC3=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.43
KDM4E B2RXH2 5/20 0.42
HPGD P15428 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
MDH2 P40926 1/20 0.42
CCNB3 Q8WWL7 1/20 0.42
MAPT P10636 5/20 0.42
TP53 P04637 2/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317747 0.89 CYP4F2 (0.45) RXFP1KDM4EHPGDALDH1A1HSD17B10
SCHEMBL24317445 0.84 PDE3B (0.42) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL24317881 0.82 MAPT (0.53) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL24317629 0.79 MAOB (0.43) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL11317546 0.79 KDM4E (0.47) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL24317641 0.75 CHEK1 (0.41) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL11322480 0.74 KDM4E (0.53) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL22532759 0.73 CDK5 (0.47) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL13941140 0.72 MAPT (0.72) KDM4EHPGDALDH1A1HSD17B10CASP1
SCHEMBL22532698 0.72 KDM4E (0.46) KDM4EHPGDALDH1A1HSD17B10CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 RXFP1 3926/4885KDM4E 791/4885HPGD 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.